顶级适应生物技术主管在收入丰厚和股价不断上涨的情况下出售了6.19亿加元的股票。 Top Adaptive Biotechnologies executives sold $6.19M in stock amid strong earnings and a rising share price.

2026年3月11日至13日, 包括CEO CEO Chad Robins、CFO Kyle Piskel和CO Julie Rubinstein在内的数位适应性生物科技顶尖执行官在2026年3月11日至13日以约13.17美元的价格售出共超过550 000股股份, Robins的销售总额达619万美元。 On March 11–13, 2026, several top executives at Adaptive Biotechnologies—including CEO Chad Robins, CFO Kyle Piskel, and COO Julie Rubinstein—sold a combined total of over 550,000 shares at prices around $13.17, with Robins’ sale totaling $6.19 million. 向证交会提交的交易反映了所有权股份的减少,尽管该公司报告Q4收入强劲,年收入增长51%,损失比预期好。 The transactions, filed with the SEC, reflect reduced ownership stakes, though the company reported strong Q4 earnings with 51% year-over-year revenue growth and a better-than-expected loss. 股票以13.17美元关闭,增加72美元,市场上限为20.3亿美元,“Moderate Buy”分析师的共识评级为“Moderate Buy”。 The stock closed at $13.17, up $0.72, with a market cap of $2.03 billion and a “Moderate Buy” analyst consensus rating.